Insight, China's Pharmaceutical Industry

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in the...

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented comprehensive Phase 3 results from the REIMAGINE 1-3 clinical...

Company Drug

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Fineline Cube Jun 8, 2026

Bayer AG (ETR: BAYN) announced positive results from a pivotal Phase III study presented at...

Company Drug

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Fineline Cube Jun 8, 2026

Novo Nordisk A/S (NYSE: NVO) presented positive Phase 2 results for zenagamtide (amycretin), its investigational...

Company Drug

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Fineline Cube Jun 8, 2026

Oricell Therapeutics Co., Ltd. announced it has received clearance from China’s National Medical Products Administration...

Company Drug

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Fineline Cube Jun 8, 2026

Boehringer Ingelheim announced positive results from two global Phase III trials of survodutide (BI 456906),...

Others

Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials

Fineline Cube Jun 8, 2026

Eli Lilly and Company (NYSE: LLY) announced additional positive results from pivotal Phase III trials...

Company Drug

Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

Fineline Cube Jun 8, 2026

Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical...

Company Drug

Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 – Novel αCD3×TGF-β Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models

Fineline Cube Jun 8, 2026

Antengene Corporation (HKG: 6996) presented compelling preclinical data for ATG-207, a novel αCD3×TGF-β bispecific fusion...

Company Drug

Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 – First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy

Fineline Cube Jun 8, 2026

Sciwind Biosciences Co., Ltd. presented groundbreaking head-to-head data from the SLIMMER-UP-SWITCH study comparing ecnoglutide against...

Company Drug

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Jun 8, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced the official commercial launch of Winrevair (sotatercept)...

Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026

Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced a strategic joint venture agreement...

Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026

Everest Medicines (HKG: 1952) announced a strategic licensing agreement with domestic peer Corxel Pharmaceuticals Limited...

Company Drug

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

Fineline Cube Jun 5, 2026

Guangzhou Lupeng Pharmaceutical Co., Ltd. announced it has received marketing approval via priority review pathway...

Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026

China’s National Healthcare Commission (NHC) announced the release of its sixth batch of pediatric drugs...

Company Drug

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Fineline Cube Jun 5, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced it has received regulatory approval from China’s...

Company Drug

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

Fineline Cube Jun 5, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced it has received clinical trial approval from...

Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026

SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow...

Company Drug

Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients

Fineline Cube Jun 5, 2026

Shanghai Bao Pharmaceuticals Co., Ltd. (HKG: 2659) announced that the National Medical Products Administration (NMPA)...

Company Drug

Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer

Fineline Cube Jun 5, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced the enrollment of the first patient in...

Insight, China's Pharmaceutical Industry

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population

Novo Nordisk’s Zenagamtide (Amycretin) Delivers 1.71% A1C Reduction and 14.6% Weight Loss in Phase 2 Type 2 Diabetes Trial – Dual GLP-1/Amylin Agonist Advances to Phase 3

Oricell Therapeutics Receives NMPA Clearance for World’s First GPC3-Targeted CAR-T Therapy in Advanced Liver Cancer – Ori-C101 Enters Confirmatory Phase II

Boehringer Ingelheim’s Survodutide Dual Agonist Achieves 34% Visceral Fat Reduction and 60% MASLD Resolution in Phase III ADA 2026 Data

Eli Lilly’s Retatrutide Delivers Unprecedented 28.3% Weight Loss and Resolves Multiple Obesity Comorbidities in Phase III TRIUMPH-1 and TRANSCEND-T2D-1 Trials

Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

Antengene Unveils ATG-207 Bispecific Fusion Protein Data at EULAR 2026 – Novel αCD3×TGF-β Molecule Shows Potent Immunomodulatory Activity in Autoimmune Models

Sciwind Biosciences Unveils Superior Weight Loss Data for Ecnoglutide vs. Semaglutide at ADA 2026 – First cAMP-Biased GLP-1 Agonist Shows 35% Greater Efficacy

MSD Launches Winrevair (Sotatercept) in China – First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Guangzhou Lupeng’s Rocbrutinib Receives NMPA Priority Approval for Relapsed/Refractory Mantle Cell Lymphoma – Fourth-Generation BTK Inhibitor Shows 63.9% Response Rate

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Sichuan Biokin Receives NMPA Go-Ahead for BL-M08D1 Bispecific Antibody in DLBCL Combination Therapy – ADC Leverages Proven BL-B01D1 Platform

Mabwell Bioscience Secures NMPA Clinical Approval for 9MW5211 in Inflammatory Bowel Disease – Highly Specific Depleting Antibody Targets Pathogenic Immune Cells

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Shanghai Bao Pharmaceuticals’ KJ103 NDA Accepted by NMPA – First-in-Class IgG Degrading Enzyme for Highly Sensitized Kidney Transplant Patients

Sichuan Biokin Enrolls First Patient in Phase III Trial of BL-M05D1 ADC for Claudin18.2-Positive Gastric Cancer

You Missed

CSPC Pharmaceutical Wins NMPA Clinical Trial Approval for SYH2083 Eye Drops – A Class 1 Innovative Small‑Molecule Ophthalmic Drug Targeting Ocular Surface Inflammation via T‑Cell Adhesion and Activation

Gilead Sciences Opens 182,000‑Square‑Foot Research Center at Foster City Headquarters – Expanding Oncology, Inflammation, and Research Data Science Capabilities as Part of a Three‑Project US Investment Program Through 2030

Windward Bio Reports Positive POLARIS‑1 Phase 2 Interim Results for HBM9378/WIN378 – An Ultra‑Long‑Acting TSLP Antibody in Asthma – as the Phase 3 Portion Begins

China’s NHC Issues Eye Health Services Work Plan for 2026–2030 – Setting 2030 Targets on Cataract Surgery Rates, Ophthalmologist Workforce Density, and County‑Level Vision Care Capacity